ABSTRACT

Conclusion:

Combination therapy may be an alternative to new drugs in the treatment of MRSA infections since in vitro studies provide promising results

Results:

Synergy was detected in 19 and 25 of the 30 strains for the VA-IPM and VA-MEM, and TEC-IPM and TEC-MEM combinations, respectively. VA-FEP synergy was detected in 19, and TEC-FEP synergy was detected in the 21 of the isolates.

Materials and Methods:

A total of 30 MRSA isolates were studied. An E-test was performed to investigate the synergy of vancomycin-imipenem (VA-IPM), vancomycin-meropenem (VA-MEM), teicoplanin-imipenem (TEC-IPM), teicoplanin-meropenem (TEC-MEM), vancomycin-cefepime (VA-FEP), and teicoplanin-cefepime (TEC-FEP) combinations

Introduction:

Glycopeptides have been used in the treatment of methicillin-resistant Staphylococcus aureus infections for the last 30 years. However, the emergence of staphylococcal isolates with reduced susceptibility to glycopeptides necessitates alternative therapies. A combination of well-known antibiotics may be an alternative approach to new drugs. The aim of this study was to investigate the synergy between glycopeptides and carba-penems, and glycopeptides and cefepime and whether there is any discre-pancy between them